Author

Tatjana Srdić‐Rajić

Institut za onkologiju i radiologiju SrbijeORCID 0000-0001-9840-6970Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Bioinformatics· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:development & morphogenesis· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1

Frequent Co-Authors

Aleksandar PavićiD· 1 shared Ana DjurićiD· 1 shared Danijel A. GaluniD· 1 shared Dušan RužićiD· 1 shared Jelena GrahovaciD· 1 shared Katarina M. NikoliciD· 1 shared Kristina ŽivićiD· 1 shared Marija OstojićiD· 1 shared

Activity by Year

2023-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Aleksandar PavićORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Nischarin agonist rilmenidine shows antimetastatic potential in pancreatic ductal adenocarcinoma

Kristina Živić, Marijana Pavlović, Marija Ostojić, Danijel A. Galun, Aleksandar Pavić, Tatjana Srdić‐Rajić, Jelena Grahovac

This study investigates the antimetastatic potential of Nischarin agonist rilmenidine in pancreatic ductal adenocarcinoma using in vitro and in vivo models.

bioRxiv · Oct 27, 2025 · PreprintCancer Biology

Correlating basal gene expression across chemical sensitivity data to screen for novel synergistic interactors of HDAC inhibitors in pancreatic carcinoma

Nemanja Djoković, Ana Djurić, Dušan Ružić, Tatjana Srdić‐Rajić, Katarina M. Nikolic

The paper uses drug-sensitivity and gene expression data to predict synergistic combinations of HDAC inhibitors in pancreatic cancer, identifying novel targets and validating synergistic interactions.

Pharmaceuticals · Feb 14, 2023Peer-reviewedBioinformatics